These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 21082944)

  • 21. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Roodman GD; Dougall WC
    Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of multiple myeloma-related bone disease].
    Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
    Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of bone disease in multiple myeloma.
    Terpos E; Berenson J; Raje N; Roodman GD
    Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research on mechanism underlying bone damage in myeloma--review].
    Zhou LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1340-4. PubMed ID: 18088497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the pathophysiology and management of bone disease in multiple myeloma.
    Terpos E; Politou M; Rahemtulla A
    Br J Haematol; 2003 Dec; 123(5):758-69. PubMed ID: 14632767
    [No Abstract]   [Full Text] [Related]  

  • 30. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloma bone disease.
    Berenson JR
    Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RANK/RANKL: regulators of immune responses and bone physiology.
    Leibbrandt A; Penninger JM
    Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
    Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
    Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloma and bone disease: "the dangerous tango".
    Epstein J; Walker R
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.